US to Impose 100% Tariff on Generic Drug Imports
US President Donald Trump has announced a phased tariff regime on imported generic medicines, with zero tariffs until August 2028, followed by a 100% tariff from August 2028 and a 200% tariff from August 2029. The move is aimed at encouraging pharmaceutical companies to shift manufacturing to the United States, but it could significantly disrupt global drug supply chains and severely impact India's export-driven generic pharmaceutical industry.
Reshoring America's Pharmaceutical Industry
The tariff plan will be implemented under Section 232 of the US Trade Expansion Act, which allows trade restrictions on national security grounds. While previous Section 232 measures focused on selected pharmaceuticals and active pharmaceutical ingredients (APIs), generic medicines had largely remained exempt.
The latest announcement specifically targets imported generic drugs, while tariffs on patented and branded medicines remain unchanged.
How the Tariff Plan Will Work
According to the announced timeline:
· August 1, 2026 – July 2028: Zero tariff on imported generic medicines.
· From August 2028: A 100% tariff will apply for one year.
· From August 2029 onward: Tariffs will double to 200%.
The two-year tariff-free period is intended to give pharmaceutical companies time to establish manufacturing facilities in the United States before the higher duties take effect.
Why the Trump Administration Is Doing This
The White House argues that the policy serves multiple objectives:
· Encourage pharmaceutical companies to relocate production to the US.
· Reduce dependence on overseas drug manufacturers.
· Strengthen national security by ensuring domestic medicine supplies.
· Use tariffs as both an incentive and penalty—rewarding companies that invest in US manufacturing while penalising those that continue importing medicines.
The proposal reflects Trump's wider "America First" industrial policy, previously seen in sectors such as steel, aluminium and strategic manufacturing.
India Faces the Biggest Challenge
India is expected to be the most affected country, as it supplies nearly 40% of all generic medicines consumed in the United States by volume.
Indian pharmaceutical companies have built their global leadership through:
· Low-cost manufacturing.
· Large-scale production capacity.
· Strong US FDA compliance.
· Efficient global supply chains.
However, tariffs of 100–200% could:
· Reduce the competitiveness of Indian exports.
· Compress profit margins.
· Lower utilisation at export-oriented manufacturing plants.
· Force companies to invest in US production facilities or diversify into alternative markets.
Possible Impact on US Healthcare
While designed to revive domestic manufacturing, the policy could also have unintended consequences for American consumers.
Potential risks include:
· Higher prices for affordable generic medicines.
· Increased healthcare costs if domestic production remains more expensive.
· Supply shortages if US manufacturing capacity does not expand quickly enough.
· Continued pressure on healthcare providers and insurance systems that depend heavily on low-cost generic drugs.
The move could also trigger legal challenges and trade disputes, particularly as Washington invokes national security provisions for pharmaceutical imports.
A Turning Point for Global Pharmaceutical Trade
Trump's phased tariff plan signals a major shift in US pharmaceutical trade policy. While it aims to strengthen domestic manufacturing and reduce dependence on foreign suppliers, it also poses significant risks for global supply chains and affordable healthcare. For India, the announcement is both a challenge and a wake-up call to diversify export markets, strengthen value-added manufacturing and reduce dependence on a single destination. The coming two years will be crucial as governments and pharmaceutical companies prepare for a policy that could fundamentally reshape the global generic medicines industry.
(With agency inputs)
